X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The company intends to use the net proceeds to fund the development of CCS1477 (inobrodib), its p300/CBP inhibitor to treat specific types of cancer including haematological malignancies and multiple myeloma.
Lead Product(s): Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: CCS1477
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 11, 2023
Details:
Inobrodib (CCS1477) is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers, to treat late stage multiple myeloma patients.
Lead Product(s): Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: CCS1477
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Investments Limited.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Product Name: CCS1477
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BrightEdge
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2022
Details:
CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with p300/CBP mutations. CellCentric plans to investigate CCS1477 both as a monotherapy and in combination with standard of care agents.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Product Name: CCS1477
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morningside Venture Investments
Deal Size: $33.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 22, 2020
Details:
CellCentric has signed an agreement with the Prostate Cancer Clinical Trial Consortium to help select and manage US sites for the ongoing evaluation of CCS1477.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CellCentric
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
